Outsourced Pharma

BE BioSol is the biologics CDMO business of Biological E. Limited, combining more than 70 years of biopharmaceutical manufacturing experience with a growing, integrated development and manufacturing platform for global biopharma partners. With a strong track record supporting regulated markets and long-standing relationships with leading pharmaceutical companies, BE BioSol provides development, analytical, technology transfer, and commercial manufacturing solutions across biologics and vaccines.

With 55+ years’ experience, Almac Pharma Services is a trusted global CDMO providing integrated pharmaceutical development, clinical and commercial manufacturing, packaging, product launch and supply chain solutions.

Get more pharma outsourcing insight with our FREE newsletter Newsletter | September 4, 2026 Successful viral vector scaleā€‘up depends on early process design, predictive models, and execution strategies that anticipate GMP realities rather than simply increasing production volume. Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.

Outsourced Pharma Capabilities Update - ADCs This digital event focuses on antibody-drug conjugates (ADCs) and how CDMOs support their development from early stages through clinical and commercial manufacturing. It highlights the importance of selecting the right partner for these complex therapies, including expertise in conjugation processes, scalability, regulatory needs, and integrated development services.

LISTEN NOW: OUR LATEST PODCAST EPISODES Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

Designed for large-scale biologics manufacturing, the facility offers up to 120KL of capacity utilizing 15KL bioreactors, with N-1 perfusion integrated into our 3,000L bioreactors. The Songdo Bio Campus brings together advanced infrastructure, digitalized operations, and globally aligned quality systems. Take a closer look inside our Songdo Bio Campus and explore the foundation being built to support our partners' future biologics programs.

For today’s biotech and pharmaceutical sponsors, biologic supply is no longer just an operational consideration. It is a strategic priority. As biologics pipelines expand, manufacturing networks become more complex, and external risks continue to evolve, ensuring uninterrupted supply requires far more than securing available capacity.

The journey from lead candidate selection to clinical development carries inherent risks that can jeopardize a program's timeline and budget. Technical obstacles like poor manufacturability, low expression levels, product quality variances, and immunogenicity risks frequently surface during these initial stages. Left unaddressed, these issues cause expensive delays, forced process re-engineering, and diminished confidence from investors and partners.

Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English Hong Kong And Florham Park, NJ (GLOBE NEWSWIRE) - HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive...

Beijing And Florence, Italy /PRNewswire/ - Gan & Lee Pharmaceuticals ("Gan & Lee"; stock code: 603087.SH) announced that it has entered into an exclusive license agreement with the multinational biopharmaceutical company The Menarini Group ("Menarini").